Biofrontera Statistics
Total Valuation
Biofrontera has a market cap or net worth of $9.54 million. The enterprise value is $10.94 million.
Important Dates
The last earnings date was Thursday, May 14, 2026, before market open.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biofrontera has 12.01 million shares outstanding. The number of shares has increased by 59.24% in one year.
| Current Share Class | 12.01M |
| Shares Outstanding | 12.01M |
| Shares Change (YoY) | +59.24% |
| Shares Change (QoQ) | +0.16% |
| Owned by Insiders (%) | 10.36% |
| Owned by Institutions (%) | 5.58% |
| Float | 8.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.22 |
| Forward PS | 0.20 |
| PB Ratio | 1.54 |
| P/TBV Ratio | 2.76 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.20, with a Debt / Equity ratio of 1.27.
| Current Ratio | 1.20 |
| Quick Ratio | 0.93 |
| Debt / Equity | 1.27 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -22.78 |
Financial Efficiency
Return on equity (ROE) is -339.04% and return on invested capital (ROIC) is -70.12%.
| Return on Equity (ROE) | -339.04% |
| Return on Assets (ROA) | -32.41% |
| Return on Invested Capital (ROIC) | -70.12% |
| Return on Capital Employed (ROCE) | -77.39% |
| Weighted Average Cost of Capital (WACC) | 7.27% |
| Revenue Per Employee | $459,585 |
| Profits Per Employee | -$117,926 |
| Employee Count | 94 |
| Asset Turnover | 2.09 |
| Inventory Turnover | 2.53 |
Taxes
In the past 12 months, Biofrontera has paid $26,000 in taxes.
| Income Tax | 26,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +24.67% in the last 52 weeks. The beta is 0.91, so Biofrontera's price volatility has been similar to the market average.
| Beta (5Y) | 0.91 |
| 52-Week Price Change | +24.67% |
| 50-Day Moving Average | 0.98 |
| 200-Day Moving Average | 0.92 |
| Relative Strength Index (RSI) | 30.00 |
| Average Volume (20 Days) | 262,741 |
Short Selling Information
The latest short interest is 76,357, so 0.64% of the outstanding shares have been sold short.
| Short Interest | 76,357 |
| Short Previous Month | 72,497 |
| Short % of Shares Out | 0.64% |
| Short % of Float | 0.92% |
| Short Ratio (days to cover) | 0.60 |
Income Statement
In the last 12 months, Biofrontera had revenue of $43.20 million and -$11.09 million in losses. Loss per share was -$1.03.
| Revenue | 43.20M |
| Gross Profit | 33.39M |
| Operating Income | -10.73M |
| Pretax Income | -11.06M |
| Net Income | -11.09M |
| EBITDA | -10.57M |
| EBIT | -10.73M |
| Loss Per Share | -$1.03 |
Full Income StatementBalance Sheet
The company has $6.33 million in cash and $7.72 million in debt, with a net cash position of -$1.40 million or -$0.12 per share.
| Cash & Cash Equivalents | 6.33M |
| Total Debt | 7.72M |
| Net Cash | -1.40M |
| Net Cash Per Share | -$0.12 |
| Equity (Book Value) | 6.07M |
| Book Value Per Share | 0.52 |
| Working Capital | 2.24M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$9.31 million and capital expenditures -$4,000, giving a free cash flow of -$9.32 million.
| Operating Cash Flow | -9.31M |
| Capital Expenditures | -4,000 |
| Depreciation & Amortization | 164,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -9.32M |
| FCF Per Share | -$0.78 |
Full Cash Flow StatementMargins
Gross margin is 77.29%, with operating and profit margins of -24.84% and -25.66%.
| Gross Margin | 77.29% |
| Operating Margin | -24.84% |
| Pretax Margin | -25.60% |
| Profit Margin | -25.66% |
| EBITDA Margin | -24.46% |
| EBIT Margin | -24.84% |
| FCF Margin | n/a |
Dividends & Yields
Biofrontera does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -59.24% |
| Shareholder Yield | -59.24% |
| Earnings Yield | -116.14% |
| FCF Yield | -97.62% |
Analyst Forecast
The average price target for Biofrontera is $6.00, which is 655.19% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.00 |
| Price Target Difference | 655.19% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 18.35% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 5, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jul 5, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |
